Pharmaceuticals Research

EpiConsults, Inc. is proficient in conducting and monitoring clinical trials, and provides clinical trial teachings to CROs, third party consultants, and talent acquisition departments. Our expertise in clinical trials encompasses various topics such as the history of clinical research, the clinical research overview, the clinical research team, ethical considerations in clinical research, clinical research study designs, research questions and hypotheses testing, sample size and power, issues related to randomization in clinical trials, selection of study participants, considerations of inclusion and exclusion criteria, research with vulnerable populations, developing study protocols and manuals for operating procedures, an overview of institutional review boards-IRB, data and safety monitoring committees, research misconduct including fabrication, falsification & plagiarism, and quality management in clinical research.

We are passionate to bring positive social change for global good. To this extend, our ultimate goal is to advocate for patients’ health and preserve their rights in clinical research. We also advocate to increase the inclusion of minorities and underserved populations like Arab Americans and Arabs in general in the Middle East and North Africa (MENA). This will help with internal and external validity of the findings of clinical trials. It’s important to note that the classification of Arabs as “white” in the US Census is primarily based on social and political considerations rather than biological or genetic ones. However, there are indeed some genetic and physiological differences between Arabs and other populations that could potentially affect their response to drugs and disease. Here are a few reasons why Arabs should be included as a separate category in clinical trials:

1- Genetic diversity: Arabs are a diverse group of people, with a range of genetic variations that can impact drug metabolism and disease susceptibility. For example, Arabs have been shown to have a high prevalence of genetic variations that affect drug metabolism, such as CYP2C19 polymorphisms.

2- Disease prevalence: Arabs are also known to have higher rates of certain diseases, such as diabetes and heart disease, compared to other populations. Including Arabs in clinical trials could help identify genetic and environmental factors that contribute to these disparities and lead to more effective prevention and treatment strategies.

3- Cultural and environmental factors: Arabs also have unique cultural and environmental factors that could impact their health outcomes. For example, dietary habits, lifestyle factors, and exposure to certain toxins or pollutants could affect their response to drugs or susceptibility to disease.

Overall, including Arabs as a separate category in clinical trials could help improve our understanding of the unique genetic and environmental factors that affect their health outcomes and lead to more personalized and effective treatments for this population.

We are also passionate about highlighting the important use of Decentralized Clinical Trail (DCT) Tools to fill the distance gap and ensure proper recruitment, enrollment and detainment of subjects in clinical trials.

Our leadership team had created the “Arab Board for Clinical research” to advocate for We advocate the inclusion of Arabs in clinical research and the promotion of Decentralized Clinical Trials with the to raise awareness about the importance of diversity in clinical trials and to supply resources and tools to help sponsors and investigators increase representation of underrepresented populations of Arab Americans and Arabs in the Arab world through best practice recruitment efforts and use of Decentralized Clinical trials tools. Please check